The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Nebieridze D.V.

National Medical Research Center for Therapy and Preventive Medicine

Safaryan A.S.

National Medical Research Center for Therapy and Preventive Medicine

Current issues of lipid-lowering therapy in patients with high-risk hypertension

Authors:

Nebieridze D.V., Safaryan A.S.

More about the authors

Journal: Russian Journal of Preventive Medicine. 2022;25(11): 42‑45

DOI: 10.17116/profmed20222511142

Read: 2319 times

Download PDF (RU)
Contact the author
Table of contents

CURRENT ISSUES OF LIPID-LOWERING THERAPY IN PATIENTS WITH HIGH-RISK HYPERTENSION
CURRENT ISSUES OF LIPID-LOWERING THERAPY IN PATIENTS WITH HIGH-RISK HYPERTENSION

To cite this article:

Nebieridze DV, Safaryan AS. Current issues of lipid-lowering therapy in patients with high-risk hypertension. Russian Journal of Preventive Medicine. 2022;25(11):42‑45. (In Russ.)
https://doi.org/10.17116/profmed20222511142

Подписка 2026 Профилактическая медицина (Russian Journal of Preventive Medicine)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
The place of non-high-density lipo­protein cholesterol and triglycerides in the asse­ssment of cardiovascular risk: Reso­lution of the Panel of Expe­rts. Russian Journal of Preventive Medi­cine. 2025;(4):7-15
Creating an index reflexing cardiovascular risk using the vital functions inte­gral analysis. Russian Journal of Preventive Medi­cine. 2025;(4):82-88
Recu­rrent coro­nary events as a persistent challenge in cardiology. The role of PCSK9 inhi­bitors in respect of this issue through the example of a local program implemented in St. Pete­rsburg. Russian Journal of Preventive Medi­cine. 2025;(9):78-86
Features of the inte­rpretation of bodily sensations by patients with arte­rial hype­rtension. Russian Journal of Preventive Medi­cine. 2025;(10):82-87
Gender features of the vascular wall condition in young people with the body weight excess. Russian Journal of Preventive Medi­cine. 2025;(11):52-58
On the path to personalized cardiology: prospects of precise asse­ssment of cardiovascular risks and predictive-prognostic diagnostics. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(2):206-215
Two years expe­rience of using alirocumab in patients with dyslipidemia. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(2):216-220
QRISK-3 cardiovascular risk asse­ssment algo­rithm in prediction of kidney transplantation outcomes. Russian Cardiology Bulletin. 2025;(2):61-69
Cere­brovascular disease in clinical practice. Reso­lution of the Expert Council of the Russian Scientific Medi­cal Society of Therapists. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):105-111
The Webiomed.DHRA deci­sion-making support system for medi­cal examinations in the Russian Fede­ration: a cost-effectiveness analysis. Medi­cal Technologies. Asse­ssment and Choice. 2025;(3):61-73
Abstract:

The article addresses the urgent issue of identifying and managing patients with high-risk arterial hypertension. The attention of medical practitioners is drawn to minimizing cardiovascular morbidity and complications. Therefore, great importance is given not only to combined antihypertensives but also to lipid-lowering therapy. Statins further reduce the risk of cardiovascular events. Unfortunately, high-risk patients have little motivation for treatment, which accounts for their lack of adherence to statin therapy. In this regard, it is reasonable to consider using a fixed-dose statin-free regimen to improve compliance and effectiveness of lipid metabolism control. However, even the most effective antihypertensive and lipid-lowering medicines can not provide maximum reduction in the cardiovascular event rate without non-drug correction of associated risk factors.

Keywords:

high-risk
antihypertensive therapy
lipid-lowering therapy
cardiovascular risk
treatment adherence

Authors:

Nebieridze D.V.

National Medical Research Center for Therapy and Preventive Medicine

Safaryan A.S.

National Medical Research Center for Therapy and Preventive Medicine

Received:

27.09.2022

Accepted:

03.10.2022

Close metadata

References:

  1. Chazova IE, Zhernakova YuV, Oshchepkova EV, Shalnova SA, Yarovaya EB, Konradi AO, Boytsov SA, Kaveshnikov VS, Serebryakova VN, Trubacheva IA. Prevalence of risk factors for cardiovascular diseases in the Russian population of patients with arterial hypertension. Kardiologiya. 2014;10:4-12. (In Russ.).
  2. 2013 ESH/ESC Guidelines for the management of arterial hypertension. Journal of Hypertension. 2013;31(7):1281-1357. https://doi.org/10.1097/01.hjh.0000431740.32696.cc
  3. Clinical recommendations. Diagnosis and treatment of arterial hypertension. Kardiologicheskij vestnik. 2015;1(10):3-30. (In Russ.).
  4. Oganov RG, Maslennikova GYa, Koltunov IE, Kalinina AM. Necessary conditions for the prevention of cardiovascular and other non-communicable diseases in the Russian Federation. Kardiovaskulyarnaya terapiya i profilaktika. 2010;9(6):4-9. (In Russ.).
  5. Williams B, Mancia G, Spiering W, et al.; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal. 2018;39(33):3021-3104. https://doi.org/10.1093/eurheartj/ehy339
  6. Sever PS, Dahlöf B, Poulter NR, et al.; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower—than—average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003; 361(9364):1149-1158. https://doi.org/10.1016/S0140-6736(03)12948-0
  7. Cannon CP, Braunwald E, McCabe CH, et al.; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22. New England Journal of Medicine. 2004;350(15):1495-1504. https://doi.org/10.1056/NEJMoa040583
  8. Pedro-Botet J, Schaefer EJ, Bakker-Arkema RG, et al. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. Atherosclerosis. 2001;158(1):183-193.  https://doi.org/10.1016/s0021-9150(01)00410-5
  9. Amarenco P, Bogousslavsky J, Callahan A 3rd, et al.; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-Dose Atorvastatin after Stroke or Transient Ischemic Attack. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL). New England Journal of Medicine. 2006;355(6):549-559.  https://doi.org/10.1056/NEJMoa061894
  10. Pitt B, Waters D, Brown WV, et al. Aggressive lipid-lowering therapy7 compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. New England Journal of Medicine. 1999;341(2):70-76.  https://doi.org/10.1056/NEJM199907083410202
  11. LaRosa JC, Grundy SM, Waters DD, et al.; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. New England Journal of Medicine. 2005;352(14):1425-1435. https://doi.org/10.1056/NEJMoa050461
  12. Brugts JJ, Yetgin T, Hoeks SE, et al. Benefitsof statins without established cfrdiovascular disease but with cardiovascular risk factors meta-analysis of randomized controlled trials. BMJ. 2009;338:b2376. https://doi.org/10.1136/bmj.b2376
  13. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal. 2011;32(14):1769-1818. https://doi.org/10.1093/eurheartj/ehr158
  14. Aronov DM, Arabidze GG, Akhmedzhanov NM, Balakhonova TV, Boitsov SA, Bubnova MG, Galyavich AS, Graziansky NA, Gornyakova NB, Gurevich VS, Denisenko AD, Drapkina OM, Yezhov MV, Eregin SYa, Zubareva MYu, Karpov RS, Karpov YuA, Kobalava ZhD, Koziolova NA, Konovalov GA, et al. Russian recommendations V revision. Rossijskij kardiologicheskij zhurnal. 2012;5(97):1-32. (In Russ.).
  15. Akhmedzhanov NM, Nebieridze DV, Safaryan AS, Vygodin VA, Shuraev AYu, Tkacheva ON, Lishuta AS. Analysis of the prevalence of hypercholesterolemia in outpatient practice (according to the ARGO study): Part I. Racional’naya farmakoterapiya v kardiologii. 2015;11(3):253-260. (In Russ.).
  16. 2019 ESC/EAS Guidelines for the management of dyslipidemias: lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140-205.  https://doi.org/10.1016/j.atherosclerosis.2019.08.014
  17. Diagnosis and correction of lipid metabolism disorders for the prevention and treatment of atherosclerosis. Russian recommendations, VII revision. Ateroskleroz i dislipidemii. 2020;1(38):7-34. (In Russ.). https://doi.org/10.34687/2219-8202.JAD.2020.01.0002
  18. Nebieridze DV, Akhmedzhanov NM, Davitashvili SA, Lishuta AS, Safaryan AS. Studying the possibility of optimizing the algorithm of statin therapy in outpatient practice. Racional’naya farmakoterapiya v kardiologii. 2020; 16(4):528-535. (In Russ.). https://doi.org/10.20996/1819-6446-2020-08-04
  19. Collaborative overview of randomised trials of antiplatelet therapy: I. Prevention of death myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialist’ Collaboration. BMJ. 1994;308:81-106.  https://doi.org/10.1136/bmj.308.6921.81
  20. de Gaetano G, Collaborative Group of the Primary Prevention Project. Lowdose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet. 2001;357(9250):89-95.  https://doi.org/10.1016/s0140-6736(00)03539-x
  21. Piepoli MF, Hoes AW, Agewall S, et al.; ESC Scientific Document Group. ESC Scientific Document Group.2016 European Guidelines on Cardiovascular Disease Prevention in Clinical Practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention and Rehabilitati7on (EACPR). European Heart Journal. 2016;37(29):2315-2381. https://doi.org/10.1093/eurheartj/ehw106
  22. Kobalava ZhD, Konradi AO, Nedogoda SV, Shlyakhto EV, Arutyunov GP, Baranova EI, Barbarash OL, Boitsov SA, Vavilova TV, Villevalde SV, Galyavich AS, Glezer MG, Grineva EN, Grinstein YuI, Drapkina OM, Zhernakova YuV, Zvartau NE, Kislyak OA, Koziolova NA, Kosmacheva ED, Kotovskaya YuV, Libis RA, Lopatin YuM, Nebieridze DV, Nedoshivin AO, Ostroumova OD, Oschepkova EV, Ratova LG, Skibitsky VV, Tkacheva ON, Chazova IE, Chesnikova AI, Chumakova GA, Shalnova SA, Shestakova MV, Yakushin SS, Yanishevsky SN. Arterial hypertension in adults. Clinical Guidelines 2020. Rossijskij kardiologicheskij zhurnal. 2020;25(3):149-218. (In Russ.). https://doi.org/10.15829/1560-4071-2020-3-3786
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.